Avaleht › Endomeetriumivähk › Alabama
Endomeetriumivähk kliinilised uuringud osariigis Alabama
19 uuringut haiguse Endomeetriumivähk jaoks otsivad osalejaid osariigis Alabama.
Linnad osariigis Alabama
Ametlik uuringutekst (inglise keeles)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
VärbamineFaas 2
Kõik vanused · Kõik sood · Uuendatud 2. okt 2026 · NCT05564377A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- GSK Investigational Site, Birmingham
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 2. okt 2026 · NCT07286331Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 2. okt 2026 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 1. okt 2026 · NCT07189871Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Alabama at Birmingham Cancer Center, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Naised · Uuendatud 28. sept 2026 · NCT05112601DESTINY-PANTUMOUR04
- Research Site, Birmingham
VärbamineVaatlusuuring
Vanused 18–130 · Kõik sood · Uuendatud 25. sept 2026 · NCT07124000Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Naised · Uuendatud 25. sept 2026 · NCT03564340A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 17. sept 2026 · NCT06952504ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
VärbamineVaatlusuuring
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 10. sept 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- USAH Mitchell Cancer Inst, Mobile
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 9. sept 2026 · NCT07166094Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
VärbamineFaas 1/2
12 Months – 30 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT04851119A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. juuli 2026 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 18–99 · Naised · Uuendatud 29. juuli 2026 · NCT03538665A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- ja veel 1
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. juuli 2026 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
VärbamineFaas 2
Vanused 18 ja vanemad · Naised · Uuendatud 16. juuli 2026 · NCT06906341Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
VärbamineFaas 1/2
Vanused 18 ja vanemad · Naised · Uuendatud 15. apr 2026 · NCT05559879SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 28. okt 2025 · NCT03452774Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.